Mesothelioma Asbestos Cancer Information

  Malignant peritoneal pleural mesothelioma asbestos cancer and treatment information 

>> What is Mesothelioma?

>> What is the Mesothelium?

>> Mesothelioma Symptoms

>> Mesothelioma Diagnosed

>> Mesothelioma Treatment

>> Mesothelioma Studies

>> Risk Factors

>> Who is at Increased Risk

>> What is Asbestos?

>> Metastatic Cancer Info

>> Mesothelioma Updates

>> Health Professionals

>> Mesothelioma advanced stages(II,III,IV)

>> Mesothelioma cellular classification

>> Mesothelioma general information

>> Mesothelioma Lawyer & Attorney Rights

>> Mesothelioma localized stage I

>> Recurrent mesothelioma

>> Different stages of mesothelioma

>> who requires examination

>> Frequently asked questions

>> Government and asbestos protection

>> hazards of asbestos

>> Environmental exposure

>> Asbestos information-sources

>> Asbestos workers protection

>> Extent of risk

>> Smoking causes higher risk

>> Usage of asbestos

>> First Aid - Emergency Instructions

>> Links

 

 

 

 

 

Mesothelioma General Information

Prognosis in this disease is difficult to assess consistently because there is great variability in the time before diagnosis and the rate of disease progression. Various surgical procedures may be possible in selected patients, providing long-term survival without cure. In large retrospective series of pleural mesothelioma patients, important prognostic factors were found to be stage, age, performance status, and histology.[1,2] For patients treated with aggressive surgical approaches, factors associated with improved long-term survival include epithelial histology, negative lymph nodes, and negative surgical margins.[3,4] For those patients treated with aggressive surgical approaches, nodal status is an important prognostic factor.[3] Median survival for malignant local pleural disease has been reported as 16 months and extensive disease as 5 months. In some instances the tumor grows through the diaphragm making the site of origin difficult to assess. Cautious interpretation of treatment results in this disease is imperative because of the selection differences among series. Effusions, both pleural and peritoneal, represent major symptomatic problems for at least two thirds of the patients. A history of asbestos exposure is reported in about 70% to 80% of all cases of mesothelioma.[1,5,6]

References

  1. Ruffie P, Feld R, Minkin S, et al.: Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 7 (8): 1157-68, 1989.  [PUBMED Abstract]

  2. Tammilehto L, Maasilta P, Kostiainen S, et al.: Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients. Respiration 59 (3): 129-35, 1992.  [PUBMED Abstract]

  3. Sugarbaker DJ, Strauss GM, Lynch TJ, et al.: Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11 (6): 1172-8, 1993.  [PUBMED Abstract]

  4. Sugarbaker D, Harpole D, Healey E, et al.: Multimodality treatment of malignant pleural mesothelioma (MPM): results in 94 consecutive patients. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-1083, 356, 1995. 

  5. Chailleux E, Dabouis G, Pioche D, et al.: Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 93 (1): 159-62, 1988.  [PUBMED Abstract]

  6. Adams VI, Unni KK, Muhm JR, et al.: Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer 58 (7): 1540-51, 1986.  [PUBMED Abstract]
 

 

 

 

# # # 
Sources of National Cancer Institute Information

 

Mesothilioma, Mesotheliema,Mesothiliema,Mesotheleoma Mesosthelioma, Masesthilioma information:

 

 

 


free hit counter